Guggenheim maintained its Buy rating on MBX Biosciences. The firm raised its price target from $88 to $150.
MBX shares were trading at $56.55. The new target implies 165% upside.
Guggenheim based its optimism on a survey of physicians who treat obesity and a comparative analysis ahead of 12-week data for MBX 4291, expected in the fourth quarter of 2026.
The firm also highlighted canvuparatide, MBX’s candidate for hypoparathyroidism. Guggenheim suggested the combined portfolio could eventually value the company at more than $8 billion.